Mycenax lands $14 million from Japan's Alfresa to anchor dual-base biologics push
What's the deal? Taiwan's Mycenax BiotechDealroom has a profile for this one. Try Dealroom → raised US$13.3M (≈$14 million) in a private placement led by Japanese pharmaceutical group AlfresaDealroom has a profile for this one. Try Dealroom → Holdings. Alfresa subscribed shares at US$0.75 apiece — a roughly 24% premium to the closing price — for about a 7.9% stake after the capital increase. Mycenax is a contract development and manufacturing organization (CDMO) for biologics.
Who's investing? Alfresa is a major Japanese prescription drug distribution and logistics group with annual revenue above US$23.8B, spanning manufacturing, wholesale, and retail. Its channels and industry resources are meant to widen Mycenax's reach in Japan.
Why now? The placement deepens a strategy already in motion. Mycenax, Alfresa, Kidswell Bio, and Chiome BioscienceDealroom has a profile for this one. Try Dealroom → are jointly funding Alfenax, a venture building a biologics plant in Akita, Japan. Mycenax and Alfresa will each hold 45% and rank as joint largest shareholders.
What's the endgame? Mycenax wants a Taiwan-Japan dual-base model: existing R&D and manufacturing in Taiwan paired with the new Akita plant for API production and aseptic filling. The facility has drawn subsidies from Japan's Ministry of Health, Labour and Welfare, covering up to 50% of eligible construction costs.
Chairman Chen Pei-chun said the company has spent more than a decade in Japan, shifting from a "CDMO service provider" into a strategic partner in the country's biopharmaceutical industry. Following the 2022 arrival of JCR PharmaceuticalsDealroom has a profile for this one. Try Dealroom → as a shareholder, Japanese investors will now collectively hold nearly 30% of Mycenax.
What could go wrong? The Akita plant is still in preparation, with operations targeted around 2030 and commercial output not expected until 2031. Returns hinge on execution and customer demand that have yet to materialize.
The signal: The deal reflects a push to localize biosimilar and biologics manufacturing in Japan, backed by both corporate capital and government policy. For Mycenax, premium-priced Japanese ownership near 30% signals partner confidence as it builds a cross-border CDMO platform aimed at Asia's biologics supply chain.
Read more: ctee.com.tw
Image credit: Generated with Gemini